Autoimmune Identification of Sudden Hearing Loss

Callejo, Francisco Javier García; Algarra, Jaime Marco; Beneyto, Magdalena; Alborch, M.H. Orts; Ventura, Antonio

doi:10.1080/0036554021000028101

Cited by 13 publications

(9 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…# 2005 Elsevier Ireland Ltd. All rights reserved. causes of ISSHL have been discussed in literature including disturbed perfusion of the cochlear artery [2], viral infection [3] and autoimmunologic response [4,5]. Furthermore, a large variety of treatment options have been tried out.…”

Section: Introductionmentioning

confidence: 99%

Idiopathic sudden sensorineural hearing loss in children

Chen

Emmerling

Ilgner

et al. 2005

International Journal of Pediatric Otorhinolaryngology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Idiopathic sudden sensorineural hearing loss in children

Chen

Emmerling

Ilgner

et al. 2005

International Journal of Pediatric Otorhinolaryngology

View full text Add to dashboard Cite

“…The exact role that TNF plays in the etiology or RAS is not well-known. Its contribution to the pathogenesis of the disease is borne out by two facts: high levels of TNF are detected in the first stages of oral ulcerations and some drugs like thalidomide or pentoxifylline with an anti-TNF action, have a high efficacy in the treatment of RAS and other ulcerative diseases such as Adamantiades-Behçet disease (7,(14)(15)(16)(17). Different authors (7,8) have observed increased levels of TNFα in serum and in saliva of RAS patients, especially in the active phase of the disease.…”

Section: Discussionmentioning

confidence: 99%

“…This stimulation is the first step of a multistage process which lead to the activation f cytotoxic t-cells and neutrophils, the necrosis of the epithelium and finally the development of an aphthous lesion. Research workers in this field have demonstrated efficacy in the prevention and treatment of RAS with some drugs that are able to reduce the production of TNF such as levamisol, thalidomide or pentoxifylline (14)(15)(16)(17). Probably their efficacy in the treatment of RAS is based in this inhibitory action.…”

Section: Discussionmentioning

confidence: 99%

Salivary levels of Tumour Necrosis Factor-alpha in patients with recurrent aphthous stomatitis

Eguia¹,

R²,

López-Vicente³

et al. 2011

Med Oral

View full text Add to dashboard Cite

Objetives: Recurrent aphthous stomatitis (RAS) is a common pathology of the oral mucosa with a complex and multifactorial etiology. Tumour Necrosis Factor-alpha (TNFα) is a cytokine with an important but not well-known role in the development of new lesions in RAS patients. Modifications of salivary levels of TNFα in RAS patients during the active periods of the disease have been measured in this work. The possible implication of TNFα in RAS etiology is also discussed. Study design: The study group was composed of 20 patients previously diagnosed with RAS and randomly selected. As a control group 10 healthy patients were also randomly selected. In both groups a TNFα assessment was carried out in non stimulated saliva. All the patients in the study group presented active lesions at the moment of the salivary sample collection. Values oscillating between 0 and 8.1 pg/ml were considered as normal. Results: Salivary TNFα levels are 2 to 5 times higher in RAS patients than those of healthy patients. Conclusions: TNFα has a possible implication in the RAS etiology and it may also have an important role in the search of new treatments for this disease.

show abstract

“…En premier lieu, nous avons cherché tous les articles concernant la myositis ossificans progressive, l'ancienne nomination de la FOP [9].…”

Section: Matériel Et Méthodesunclassified

“…Pour 13 des 32 cas la possibilité de maintenir une bonne hygiène orale est mentionnée dans l'article [6, 9, 11-13, 15, 17, 20], et pour 9 de ces 13 cas [6,9,11,12,15,17,20] celle-ci est difficile à cause de la limitation d'ouverture buccale. Ce problème de contrôle de plaque dentaire entraine le développement de pathologies dentaires de type caries et abcès dans 9/32 cas [2, 6, 11-13, 15, 17] et 6 de ces cas ont des difficultés à maintenir une bonne hygiène bucco-dentaire.…”

Section: Prise En Charge Dentaireunclassified

Troubles oro-faciaux dans Fibrodysplasia ossificans progressiva. Revue systématique.

García

García-López

2019

Nemesis

View full text Add to dashboard Cite

La fibrodysplasia ossificans progressiva ou myosite ossifiante est une maladie autosomique dominante très rare. La maladie est caractérisée par l’apparition progressive de calcifications ectopiques dans les tendons, les muscles striés, les ligaments et les fascias. Elles entrainent une perte de mobilité progressive du corps allant jusqu’à un handicap physique sévère. Le présent travail est une revue systématique de la littérature concernant les aspects oro-faciaux de cette pathologie rare. Des pistes de prise en charge de ces patients au niveau dentaire et maxillo-facial sont aussi proposées.

show abstract

Autoimmune Identification of Sudden Hearing Loss

Cited by 13 publications

References 7 publications

Idiopathic sudden sensorineural hearing loss in children

Idiopathic sudden sensorineural hearing loss in children

Salivary levels of Tumour Necrosis Factor-alpha in patients with recurrent aphthous stomatitis

Troubles oro-faciaux dans Fibrodysplasia ossificans progressiva. Revue systématique.

Contact Info

Product

Resources

About